A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered Via Intravitreal Injection in Participants With Neovascular Age-related Macular Degeneration
The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (nAMD)
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究連絡先
研究連絡先
- 名前:Amgen Call Center
- 電話番号:866-572-6436
- メール:medinfo@amgen.com
研究場所
-
-
California
-
Fullerton、California、アメリカ、92835-3432
- 募集
- Retina Consultants of Orange County
-
Long Beach、California、アメリカ、90607
- 募集
- South Coast Retina Center - RCA
-
Modesto、California、アメリカ、95356
- 募集
- Retinal Consultants Medical Group, Inc - Modesto (RCA)
-
Pasadena、California、アメリカ、91107
- 募集
- California Eye Specialists Medical Group, Inc
-
Sacramento、California、アメリカ、95825
- 募集
- Retinal Consultants Medical Group, Inc - Sacramento - Parkcenter Drive (RCA)
-
Santa Barbara、California、アメリカ、93103
- 募集
- California Retina Consultants
-
-
Colorado
-
Colorado Springs、Colorado、アメリカ、80909-1183
- 募集
- Retina Consultants of Southern Colorado (Colorado Springs)- RCA
-
Colorado Springs、Colorado、アメリカ、80909
- 募集
- Retina Consultants of Southern Colorado (Pueblo)- RCA
-
Lakewood、Colorado、アメリカ、80228
- 募集
- Colorado Retina Associates (RCA)
-
-
Connecticut
-
Waterford、Connecticut、アメリカ、06385
- 募集
- Retina Group of New England
-
-
Florida
-
Miami、Florida、アメリカ、33143
- 募集
- Medeye Associates - Research
-
Naples、Florida、アメリカ、34103-4457
- 募集
- Retina Consultants of Southwest Florida - Naples
-
Pensacola、Florida、アメリカ、32503
- 募集
- Advanced Research, LLC
-
-
Illinois
-
Chicago、Illinois、アメリカ、60452
- 募集
- University Retina and Macula Associates, PC
-
Elmhurst、Illinois、アメリカ、60126
- 募集
- Retina Associates
-
-
Indiana
-
Carmel、Indiana、アメリカ、46032
- 募集
- Associated Vitreoretinal and Uveitis Consultants
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21209
- 募集
- The Retina Care Center- Baltimore (PRISM Vision Group)
-
Hagerstown、Maryland、アメリカ、21740-5846
- 募集
- Mid Atlantic Retina Specialists
-
Towson、Maryland、アメリカ、21204-6833
- 募集
- Retina Specialists
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- 募集
- Ophthalmic Consultants of Boston
-
-
Minnesota
-
Edina、Minnesota、アメリカ、55435
- 募集
- Retina Consultants of Minnesota (RCM) - St. Louis Park
-
-
Mississippi
-
Madison、Mississippi、アメリカ、39110
- 募集
- Mississippi Retina Assoc
-
-
Missouri
-
St Louis、Missouri、アメリカ、63128
- 募集
- The Retina Institute, Research Retina Institute (RCA)
-
-
New Jersey
-
Bloomfield、New Jersey、アメリカ、07003
- 募集
- Envision Ocular, LLC
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87109
- 募集
- Vision Research Center Eye Associates of New Mexico
-
-
New York
-
Liverpool、New York、アメリカ、13088
- 募集
- Retina Vitreous Surgeons of CNY, PC
-
Oceanside、New York、アメリカ、11572
- 募集
- Ophthalmic Consultants of Long Island - Research
-
Scarsdale、New York、アメリカ、10583-5032
- 募集
- Long Island Vitreoretinal Consultants(RCA Network)
-
-
North Carolina
-
Raleigh、North Carolina、アメリカ、27607-7514
- 募集
- North Carolina Retina Associates
-
Wake Forest、North Carolina、アメリカ、27587
- 募集
- NC Retina Associates- RCA
-
-
Ohio
-
Dublin、Ohio、アメリカ、43016
- 募集
- Midwest Retina - Main Office
-
-
Pennsylvania
-
Kingston、Pennsylvania、アメリカ、18704-4801
- 募集
- Eye Care Specialists - Kingston
-
-
South Carolina
-
Beaufort、South Carolina、アメリカ、29902
- 募集
- Retina Consultants of South Carolina, Charleston Neuroscience institute - Blufffon (RCA)
-
Charleston、South Carolina、アメリカ、29414-5896
- 募集
- Charleston Neuroscience Institute
-
Columbia、South Carolina、アメリカ、29169
- 募集
- Palmetto Retina Center - Main (RCA)
-
Ladson、South Carolina、アメリカ、29456
- 募集
- Retina Consultants of South Carolina, Charleston Neuroscience Institute- Ladson (RCA)
-
Mt. Pleasant、South Carolina、アメリカ、29464
- 募集
- Retina Consultants of South Carolina, Charleston Neuroscience Institute- Mount Pleasant (RCA)
-
West Columbia、South Carolina、アメリカ、29169
- 募集
- Palmetto Retina Center, Florence (RCA)
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- 募集
- Tennessee Retina PC
-
-
Texas
-
Arlington、Texas、アメリカ、76012
- 募集
- Texas Retina Associates (TRA) - Arlington
-
Austin、Texas、アメリカ、78705
- 募集
- Austin Retina Associates
-
Austin、Texas、アメリカ、78705
- 募集
- Austin Retina Associates - Ophthalmology/Retina
-
Bellaire、Texas、アメリカ、77401
- 募集
- Retina Consultants of Texas - Bellaire
-
Dallas、Texas、アメリカ、75231
- 募集
- Texas Retina Associates (TRA) - Dallas Main
-
Fort Worth、Texas、アメリカ、76104
- 募集
- Texas Retina Associates - Fort Worth
-
Houston、Texas、アメリカ、77401
- 募集
- Retina Consultants of Texas - Katy Retina Center
-
Katy、Texas、アメリカ、77494
- 募集
- Retina Consultants of Texas - The Woodlands
-
San Antonio、Texas、アメリカ、78240
- 募集
- Retinal Consultants of Texas- San Antonio
-
Schertz、Texas、アメリカ、78154
- 募集
- Retina Consultants of Texas - Schertz
-
Willow Park、Texas、アメリカ、76087
- 募集
- Strategic Clinical Research Group, LLC
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84107
- 募集
- Retina Associates of Utah - Retina Specialist
-
-
Virginia
-
Falls Church、Virginia、アメリカ、22042-2349
- 募集
- Emerson Clinical Research- Virginia Retina Specialists
-
-
Washington
-
Bellevue、Washington、アメリカ、98004-3779
- 募集
- Vitreoretinal Associates of Washington
-
Silverdale、Washington、アメリカ、98383
- 募集
- Retina Center NW PLLC
-
Spokane、Washington、アメリカ、99204-2509
- 募集
- Spokane Eye Clinic (OCT and optical exam
-
-
-
-
-
Madrid、スペイン、28041
- 募集
- Hospital Universitario 12 de Octubre - Oftalmología
-
-
Barcelona
-
San Cugat Del Valles、Barcelona、スペイン、08190
- 募集
- Hospital Universitari General de Catalunya
-
-
Catalonia
-
Barcelona、Catalonia、スペイン、8021
- 募集
- Centro de Oftalmologia Barraquer (Barraquer Ophthalmology Centre)
-
-
Navarre
-
Navarra、Navarre、スペイン、31008
- 募集
- Clinica Universidad de Navarra - Oftalmología
-
-
Sevilla
-
Santiago de Compostela、Sevilla、スペイン、15706
- 募集
- Hospital Provincial De Conxo - Oftalmología
-
-
-
-
Bratislava Region
-
Bratislava、Bratislava Region、スロバキア、851 07
- 募集
- Univerzitna nemocnica Bratislava - Ocna klinika SZU a UNB
-
Bratislava、Bratislava Region、スロバキア、81108
- 募集
- Univerzitna nemocnica - Nemocnica svateho Michala, a.s. - Ocna ambulancia
-
Bratislava、Bratislava Region、スロバキア、821 03
- 募集
- CMO Bratislava
-
Bratislava、Bratislava Region、スロバキア、826 06
- 募集
- Univerzitna nemocnica Bratislava - Klin. oftalmologie LFUK a UNB
-
Bratislava、Bratislava Region、スロバキア、851 07
- 募集
- Oftalmologicke centrum ProCare Betliarska
-
-
Košice Region
-
Trebišov、Košice Region、スロバキア、075 01
- 募集
- NsP Trebisov, a.s. - Ocne oddelenie
-
-
Nitra Region
-
Nitra、Nitra Region、スロバキア、950 01
- 募集
- Fakultna Nemocnica Nitra - Ocna Klinika
-
-
Trenčín Region
-
Banska Bystrica、Trenčín Region、スロバキア、975 17
- 募集
- FNsP F.D.R. Banska Bystrica - II. Ocna klinika SZU
-
Trenčín、Trenčín Region、スロバキア、911 71
- 募集
- Fakultna nemocnica Trencin - Ocna klinika
-
-
Žilina Region
-
Žilina、Žilina Region、スロバキア、012 07
- 募集
- Fakultna nemocnica s poliklinikou Zilina - Ocne oddelenie
-
-
-
-
-
Prague、チェコ、100 34
- 募集
- FN Kralovske Vinohrady - Oftalmologicka klinika
-
-
Hradec Králové Region
-
Náchod、Hradec Králové Region、チェコ、547 01
- 募集
- Visus, spol. s r.o. - Nachod
-
-
Ostrava-město
-
Ostrava - Poruba、Ostrava-město、チェコ、708 52
- 募集
- Fakultni nemocnice Ostrava - Ocni klinika
-
-
Prague
-
Prague、Prague、チェコ、150 00
- 募集
- AXON clinical
-
Prague、Prague、チェコ、128 08
- 募集
- Vseobecna fakultni nemocnice v Praze - Ocni klinika
-
-
Stredoceský Kraj
-
Mladá Boleslav、Stredoceský Kraj、チェコ、293 01
- 募集
- Oblastni nemocnice Mlada Boleslav, a.s., nemocnice Stredoceskeho kraje - Klaudianova nemocnice
-
-
-
-
-
Budapest、ハンガリー、H-1062
- 募集
- Eszak-pesti Centrumkorhaz - Honvedkorhaz
-
-
Baranya Varmegye
-
Dombóvár、Baranya Varmegye、ハンガリー、7621
- 募集
- Ganglion Orvosi Kozpont - Nozologen Kft - Szemeszet
-
-
Csongrad-Csanad Varmegye
-
Szeged、Csongrad-Csanad Varmegye、ハンガリー、6720
- 募集
- Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Szemeszeti Klinika
-
-
Hajdú-Bihar
-
Debrecen、Hajdú-Bihar、ハンガリー、4032
- 募集
- Debreceni Egyetem OEC - Ophthalmology
-
-
-
-
-
Bytom、ポーランド、41-902
- 募集
- Caminomed Sp. z o.o.
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz、Kuyavian-Pomeranian Voivodeship、ポーランド、85-631
- 募集
- OFTALMIKA Sp. z o. o.
-
-
Lesser Poland Voivodeship
-
Krakow、Lesser Poland Voivodeship、ポーランド、31-411
- 募集
- COMO Centrum Okulistyki Sp. z o.o.,
-
-
Lódzkie
-
Lodz、Lódzkie、ポーランド、90-302
- 募集
- Santa Familia PTG Lodz
-
-
Masovian Voivodeship
-
Krakow、Masovian Voivodeship、ポーランド、30-363
- 募集
- Szpital sw. Rozy Sp. z o.o.
-
-
Pomeranian Voivodeship
-
Warszawa、Pomeranian Voivodeship、ポーランド、01-258
- 募集
- Warszawski Szpital Okulistyczny
-
-
Warmian-Masurian Voivodeship
-
Olsztyn、Warmian-Masurian Voivodeship、ポーランド、10-424
- 募集
- Centrum Diagnostyki i Mikrochirurgii Oka-Lens Sp. z o.o.
-
-
-
-
-
Riga、ラトビア、1002
- 募集
- P.Stradina Clinical University Hospital - Ophthalmology
-
Riga、ラトビア、LV-1002
- 募集
- Riga East University Hospital - Department of Ophthalmology, Clinical Center "Bikernieki"
-
-
Riga
-
Riga、Riga、ラトビア、LV-1009
- 募集
- Latvian American Eye Center
-
-
-
-
Kaunas County
-
Kaunas、Kaunas County、リトアニア、50009
- 募集
- Lietuvos Sveikatos Mokslu Universitetas (LSMU) - Kauno Klinikos - ophthalmology
-
-
-
-
-
Fukushima、日本、9601295
- 募集
- Fukushima Medical University Hospital - Ophthalmology
-
Tokyo、日本、101-8309
- 募集
- Nihon University Hospital - Ophthalmology
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、460-0008
- 募集
- SUGITA EYE HOSPITAL - Ophthalmology
-
-
Fukuoka
-
Fukuoka、Fukuoka、日本、812-0011
- 募集
- Hayashi Eye Hospital
-
-
Hyōgo
-
Amagasaki、Hyōgo、日本、660-8550
- 募集
- Hyogo Prefectural Amagasaki General Medical Center - Ophthalmology
-
-
Osaka
-
Tennoji-Ku、Osaka、日本、543-0001
- 募集
- University of the Ryukyus Hospital - Ophthalmology
-
-
Tokyo
-
Meguro-ku、Tokyo、日本、152-8902
- 募集
- Tokyo Medical Center - Ophthalmology
-
Sendai、Tokyo、日本、984-8560
- 募集
- Tokyo Medical University Hachioji Medical Center - Ophthalmology
-
-
Yamaguchi
-
Ube、Yamaguchi、日本、755-8505
- 募集
- Yamaguchi University Hospital
-
Ube、Yamaguchi、日本、7558505
- 募集
- Tokushima University Hospital - Ophthalmology
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Men or women ≥ 50 years old, capable of giving signed informed consent
- Active, treatment-naïve subfoveal CNV lesions secondary to nAMD including juxtafoveal lesions that affect the fovea as confirmed by SD-OCT and FA in the study eye (SE)
- Total area of CNV (including both classic and occult components) > 50% of the total lesion area in the SE
- The BCVA letter score ≥ 24 and ≤ 78 letters, in the SE
- Presence of intra and/or subretinal fluid affecting the central subfield of the SE as identified by SD-OCT attributable to active CNV. The central subfield is defined as a circle with a diameter of 1 mm, centered on the fovea
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply at either screening or baseline, unless otherwise indicated per protocol:
- Total lesion size > 12 disc areas (30.5 mm2) including blood, scars, and neovascularization, in the study eye
- Scar, fibrosis, or atrophy involving the central subfield in the study eye
- Scar or fibrosis involving > 50% of the total lesion in the study eye
- Presence of retinal pigment epithelium tears or rips involving the macula in the study eye
- History of any vitreous hemorrhage ≤ 4 weeks (28 days) before randomization in the study
- Presence of other causes of CNV, including pathologic myopia (spherical equivalent ≥ 8 diopters negative or axial length ≥ 25 mm), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study
- Uncontrolled glaucoma (defined as IOP >25 mmHg despite treatment with anti-glaucoma medication) in the study eye
- History or clinical evidence of DR, DME, idiopathic autoimmune uveitis, or any other vascular disease affecting the retina, other than nAMD in either eye
- Evidence of active extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in either eye at the time of screening or randomization
- Uncontrolled blood pressure (defined as systolic >160 mmHg or diastolic >95 mmHg). Blood pressure needs to be stable for at least 12 weeks (84 days) prior to screening
- Any prior or concomitant ocular or systemic treatment (with an investigational or approved, anti VEGF or anti-VEGF/anti-angiopoietin agent) in the SE, or surgery for nAMD in the SE, except dietary supplements or vitamins
- History or evidence of any other clinically significant disorder, condition, disease or clinical laboratory abnormality that, in the opinion of the investigator or study medical monitor, if consulted, would pose a risk to participant safety or interfere with the study evaluation or results interpretation
- Other protocol-specified exclusion criteria
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:ABP 938 8 mg
Participants will receive intravitreal ABP 938 8 mg injections at Baseline, Week 4, and Week 8. Participants will then be assessed at scheduled study visits, with Dose Regimen Adjustment (DRA) decisions beginning at Week 16 based on predefined disease-activity criteria. Injections will be administered at protocol-defined intervals ranging from every 4 to 16 weeks through the end of the study. |
IVT injection |
|
アクティブコンパレータ:Aflibercept (US) 8 mg
Participants will receive intravitreal Aflibercept (US) 8 mg injections at Baseline, Week 4, and Week 8. Participants will then be assessed at scheduled study visits, with DRA decisions beginning at Week 16 based on predefined disease-activity criteria. Injections will be administered at protocol-defined intervals ranging from every 4 to 16 weeks through the end of the study. |
IVT injection
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Change From Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score
時間枠:Baseline and Week 12
|
Baseline and Week 12
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Percentage of Participants With Absence of Intraretinal Fluid (IRF) and Subretinal Fluid (SRF) in the Center Subfield, as Assessed by Spectral-Domain Optical Coherence Tomography (SD-OCT)
時間枠:Week 16
|
Week 16
|
|
Change from Baseline in BCVA as measured by ETDRS letter score
時間枠:Baseline to Week 48
|
Baseline to Week 48
|
|
Percentage of Participants Who Gained at Least 15 Letters of Vision From Baseline to Week 24
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Percentage of Participants Who Gained at Least 15 Letters of Vision From Baseline to Week 48
時間枠:Baseline to Week 48
|
Baseline to Week 48
|
|
Change From Baseline in Choroidal Neovascularization (CNV) Area Size as Measured by Fluorescein Angiography (FA)
時間枠:Baseline to Week 48
|
Baseline to Week 48
|
|
Change From Baseline in Central Subfield Thickness (CST) as Measured by SD-OCT
時間枠:Baseline to Week 48
|
Baseline to Week 48
|
|
Percentage of Participants Who Met Protocol-Defined DRA Criteria, as Determined by Protocol-Specified Clinical and Imaging Assessments
時間枠:Week 16 and Week 20
|
Week 16 and Week 20
|
|
Percentage of Participants Who Met Protocol-Defined DRA Criteria, as Determined by Protocol-Specified Clinical and Imaging Assessments
時間枠:Week 48
|
Week 48
|
|
Number of Participants Who Experienced Ocular Treatment-Emergent Adverse Events (TEAEs)
時間枠:Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Experienced Non-Ocular TEAEs
時間枠:Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Experienced Treatment-Emergent Events of Interest (EOI)
時間枠:Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Experienced Treatment-Emergent Serious Adverse Events (TESAEs)
時間枠:Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Developed Binding Antidrug Antibodies (ADAs)
時間枠:Baseline up to Week 48
|
Baseline up to Week 48
|
|
Free serum concentrations of ABP 938 8 mg
時間枠:Week 16, week 24 and 48 (End of Study)
|
Week 16, week 24 and 48 (End of Study)
|
|
Free serum concentrations of Aflibercept (US) 8 mg
時間枠:Week 16, week 24, and 48 (End of Study)
|
Week 16, week 24, and 48 (End of Study)
|
|
Pharmacokinetic (PK) parameters of ABP 938 8mg derived from concentration - time profiles following the first dose in a PK substudy
時間枠:From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
|
Pharmacokinetic parameters of Aflibercept (US) 8 mg derived from concentration - time profiles following the first dose in a PK substudy
時間枠:From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:MD、Amgen
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 20250115
- 2025-523500-72-00 (Ctis)
- 2025 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD 共有時間枠
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD 共有アクセス基準
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。